Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Not yet recruiting 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 7INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Head & Neck 3Breast 1

Conditions

Breast Neoplasms 150Colorectal Neoplasms 82Stomach Neoplasms 77Neoplasms 35Neoplasm Metastasis 35Pancreatic Neoplasms 25Triple Negative Breast Neoplasms 22Parkinson Disease 4, Autosomal Dominant Lewy Body 16Adenocarcinoma 13Esophageal Neoplasms 12Carcinoma, Non-Small-Cell Lung 11Colonic Neoplasms 10Biliary Tract Neoplasms 10Rectal Neoplasms 9Carcinoma, Hepatocellular 9Brain Neoplasms 8Squamous Cell Carcinoma of Head and Neck 7Adenocarcinoma Of Esophagus 7Solid Tumor 6Ovarian Neoplasms 6Cholangiocarcinoma 6Nasopharyngeal Carcinoma 5Gastrointestinal Neoplasms 5Esophageal Squamous Cell Carcinoma 5Recurrence 4Nasopharyngeal Neoplasms 4Advanced Solid Tumors 4Sarcoma 3Melanoma 3Head and Neck Neoplasms 3

Interventions

Dexamethasone 64Cyclophosphamide 35pomalidomide 34Lenalidomide 34Rituximab 31Bortezomib 30venetoclax 28fludarabine 27Gemcitabine 21carfilzomib 20Paclitaxel 19pembrolizumab 17daratumumab 17Cisplatin 16Carboplatin 15Calcium Dobesilate 14Azacitidine 14ibrutinib 12Docetaxel 12Cytarabine 12obinutuzumab 11Nivolumab 11durvalumab 10Injections 10Doxorubicin 10Bevacizumab 10selinexor 9cemiplimab 9blinatumomab 9Cetuximab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Recurrence × Capecitabine × Clear all
NCT07406542 2026-02-12

A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer

CSPC Megalith Biopharmaceutical Co.,Ltd.

Phase 3 Not yet recruiting
400 enrolled
Breast

Breast Neoplasms, Recurrence

NCT05126719 2026-02-06

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma

Shanghai Miracogen Inc.

Phase 2 Active not recruiting
238 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Recurrence

NCT06976190 2026-01-20

Magic-C002

Shanghai Miracogen Inc.

Phase 3 Recruiting
446 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Recurrence

NCT06892431 2025-03-25

JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer

Shanghai JMT-Bio Inc.

Phase 2 Not yet recruiting
150 enrolled
Head & Neck

Nasopharyngeal Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡